U.S. health reform
A time of transition
As health care reforms in the U.S. gain traction, stakeholders are recalibrating their roles and relationships across the healthcare value chain. How are companies and organizations addressing issues around cost and value and adapting innovative solutions in this new era of reform?
The Financial Times, in association with Deloitte, are proud to present the FT U.S. Healthcare & Life Sciences Conference, May 15, 2014 in New York. Explore Deloitte's latest insights into today's top industry issues to be discussed at the conference.
The Financial Times U.S. Healthcare & Life Sciences Conference
Deloitte is proud to once again be the lead sponsor of the Financial Times U.S. Healthcare and Life Sciences Conference (follow #FTUSHC on Twitter), one of America's pre-eminent industry events attended by leading executives, government decision makers, investors, analysts and other specialist providers. Join over 200 senior life sciences and health care executives to debate, discuss, and respond to today's critical industry issues and to look at the impact of reform on the industry. Use FTDEL when registering to receive a 25% discount off the current registration rate. Learn more at www.ft-live.com/USHC2014.
May 15, 2014
New York Hilton Midtown
New York, NY
Deloitte Global Insights podcast
Listen to the podcast, featuring Deloitte life sciences and health care industry leaders discussing the Financial Times U.S. Healthcare and Life Sciences Conference topics.
What has been the impact of reform to date on the life sciences industry in the U.S. and the key learnings
How can the potential of mobile health be harnessed to make a real and tangible impact on health costs and transformation?
Pay-for-performance reforms in the U.S. are taking hold but what uncertainties remain?
Pete Mooney, Managing Director for the Global Life Sciences and Health Care Industry Practice of Deloitte Touche Tohmatsu Limited.
Terry Hisey is Vice Chairman and Life Sciences Sector Leader for Deloitte LLP in the United States.
Dr. Harry Greenspun is the Senior Advisor for Health Care Transformation & Technology at the Deloitte Center for Health Solutions, part of Deloitte LLP in the United States.
Stephen Heasley, Global Online Communications, Deloitte Touche Tohmatsu Limited.
2014 Global health care sector outlook
The coming years look to be a positive but challenging time for the global health care sector; one in which many historic business models and operating processes will no longer suffice amid rising demand, continued cost pressures, lack of or inadequate care facilities, and rapidly evolving market conditions. The report examines the current state of the global health care sector, provides a snapshot of activity in a number of geographic markets, and suggests considerations for stakeholders as they address funding, cost and other issues while seeking to grow revenue and market share in 2014 and beyond.
Invigorating biopharma: How the three rules can drive superior performance
The biopharmaceutical industry is at a transformative point in its history. For decades, the industry has had an outstanding run of success, finding therapies for some of the most significant health issues of our time and generating strong returns as a result. These successes, both medical and business, were predicated on a strong model of productive R&D generating innovative products that drove growth and delivered considerable value to patients. Now, however, disruption and challenge are found throughout the industry in its thinning pipelines, expanding lists of stakeholders, narrowing distribution channels, and increasing regulatory and value requirements. How can biopharma companies emerge with new strategies that are again oriented toward non-price value and growth?
2014 Global life sciences sector outlook
Despite increased regulation, pricing pressures and the effects of health care reform in many countries, the global life sciences sector is exhibiting resilience and reinvention as it employs new research and development (R&D) and business models to cost-effectively deliver innovation, value, and improved patient outcomes. The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
Health care reform encompasses legislation that has been signed in the recent past related to the access and delivery of healthcare, notably the Affordable Care Act (ACA) passed in 2010, as well as broader, nonreversible trends in the market. Reform culminates into a heightened focus on reducing cost while increasing the quality of care, which will likely force a new definition of innovation to emerge for biopharma.
New demands from health plans and health care providers to improve the quality of care without increasing overall health care cost will increase the demand for products that demonstrate improvements in health outcomes over existing treatment.
Measuring the return from pharmaceutical innovation: Weathering the storm?
This Deloitte report is the fourth in an annual series exploring the pharmaceutical industry’s performance in generating a return from its investment in new product innovation. For the last four years Deloitte and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines. The cohort of companies comprises the 12 companies reporting the highest absolute research and development (R&D) spend for 2008-2009. The late stage pipeline includes those compounds which are either in Phase III development or submitted for approval.
Recent changes in the US health care ecosystem are having a profound and transformational impact on the medical technology industry. The Affordable Care Act has catalyzed changes in how med tech customers define value and which stakeholders are involved in decision making. While it has historically been a jewel of American manufacturing—one of the few domestic manufacturing industries that is a net exporter—med tech faces challenges to the legacy business models and strategic choices that these companies have used to excel in the past. More than ever, success requires a clear and consistent focus on delivering differentiated value and performance to customers.
Consumer interest in mobile health (mHealth) is strong and its potential to improve health care is high. Despite this interest, however, Deloitte’s 2013 Survey of U.S. Health Care Consumers shows that consumer adoption of mobile health technologies remains limited. And yet, the tools for mHealth are already in consumers’ hands – nine in 10 Americans own a cell phone; over half of these are smart phones. One in three uses their phone to look for health information. Consumers are comfortable with mobile-enabled shopping, travel and banking so, why not health care? Privacy and security concerns, skepticism about the accuracy of apps and a gap in what some consumers say they want and the health care industry’s current capabilities are limiting factors.